Estuary Biotherapeutics raised $103 million to advance preclinical gene therapy candidates targeting inherited kidney disease, describing two programs built for the most common disorder in the category. The capital provides extended runway for IND-enabling work and early manufacturing scale-up. A separate report indicates Biogen-backed Estuary previously secured $93 million in a Series A led by RA Capital for additional liver-disease gene therapy work tied to inherited kidney pathways. Together, the financings show sustained investor appetite for platform-driven gene therapy development where clinical risk can be mitigated through layered evidence generation.